From Research at med.fsu.edu Mon Jul 1 08:00:43 2019 From: Research at med.fsu.edu (Med Research) Date: Mon, 1 Jul 2019 12:00:43 +0000 Subject: Weekly Funding Opportunities In-Reply-To: References: <60E19361B71BE04F835C1FB3C18361BE019043CB68@FSUCOM128.med.ad.fsu.edu> Message-ID: <60E19361B71BE04F835C1FB3C18361BE019043FE3C@FSUCOM128.med.ad.fsu.edu> TD Ameritrade Ready Challenge: Better Health The TD Ready Challenge is an annual North American initiative that has up to ten $1 million (CAD) grants available to catalyze innovative solutions for a changing world. Recipients will be organizations that have impactful and measurable solutions that will help open doors for a more inclusive and sustainable tomorrow. The 2019 Problem Statement: Better Health Research has shown a clear link between financial health and physical health. People with strong financial health experience less stress, access regular preventative healthcare, make healthier choices and take prescribed medication. People with strong physical health are able to work longer and are better equipped to deal with financial issues. Today, advances in healthcare are helping many people lead healthier lives.1 One reason is an increase in the ability to screen for and detect diseases at an earlier stage. That way interventions can occur sooner, making them less costly and more effective. Unfortunately, research has also shown that access to quality healthcare, including awareness and advancements related to early screening and intervention, may not be experienced equally across all communities and may differ based on a number of factors. These factors include race, ethnicity, socioeconomic status and geographic location. Specifically, we are seeking to fund programs, grounded in clinical solutions, that focus on preventative efforts, such as screening, early detection and intervention innovations, aimed at reducing the onset, development and severity of chronic disease2 and other illnesses and satisfy any one or both of the following criteria: * Aim to improve on existing healthcare practices and services to help reach underserved and remote populations (Canada) and/or low to moderate income populations (U.S) * Utilize technologies to reach underserved and remote populations (Canada) and/or low to moderate income populations (U.S) Due August 23, 2019. Med-RA deadline to receive draft documents: August 9, 2019. Curing Kids Cancer: Innovative Research Awards The goal of these grants is to overcome barriers to clinical application of new treatment approaches for childhood cancer. A priority is to fund projects that have already shown great promise, but that have a specific funding need to move forward. The three main focus areas for this RFP are * Cancer immunotherapy / targeted therapy * High-grade brain tumors * Therapeutic targeting through genomics / epigenetics Application of novel technologies in these areas are welcome. Applications to fund correlative studies associated with clinical trials in the focus areas will be considered. Funding for the associated clinical trial must have already been secured and applications must include a description of the developmental pathway for the therapeutic approach. Two types of one-year grants will be awarded: * Collaborative: One multi-institutional collaborative grant award of $300,000 * Individual: Two individual grant awards of $150,000 each 10% IDC. Due September 9, 2019. Med-RA deadline to receive draft documents: August 23, 2019. National Center for Responsible Gaming: Seed Grants for Research on Gambling Disorder In support of its mission, the National Center for Responsible Gaming is inviting applications for the 2019 Seed Grant for Research on Gambling Disorder. Through the program, grants of up to $30,000 (plus 15 percent for facilities and administration costs) will be awarded to proposals with high scientific merit that explore the etiology, prevention, and treatment of gambling disorder. The program supports a variety of research activities, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; the development of research methodologies; and the development of new research technology. The 2019 call for proposals is intended to support research with direct implications for gambling policy, although proposals based on topics other than policy are welcome. Due August 1, 2019. Med-RA deadline to receive draft documents: July 18, 2019. Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed) The goal of this Funding Opportunity Announcement (FOA) is to support translational research that provides strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes outcomes relevant to obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition, kidney and urological diseases, and hematology. Additional information concerning programmatic areas at NIDDK is available at https://urldefense.proofpoint.com/v2/url?u=http-3A__www.niddk.nih.gov_research-2Dfunding_research-2Dprograms_Pages_default.aspx&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=WdhVA7LVBxxZFMapOhBO8mYE8EtpCVPBO5Ub4a5K7a0&s=S9u-_NqlZMOG7j7VJ2Mzh-U_Hfp91DxmBJEq_gOZe7Q&e= and applicants are strongly encouraged to discuss research priorities with the Scientific Contact. The objective of this FOA is to stimulate early-stage preclinical validation of therapeutic leads (that need not be finalized therapeutics, henceforth called ?therapeutic leads?) such as small molecules or non-viral biologics that are not currently a focus within the biotechnology and pharmaceutical industries. It is expected that there is significant novelty in the target, small molecule, or non-viral biologic and in how the resulting therapeutic would differentiate from existing therapies. This must be articulated clearly in the application. It is not intended to support research focused on understanding normal biology, disease processes, generating lists of putative new targets, or identifying new therapeutic uses for existing compounds. At the end of the project period, a successful project will have provided a significant contribution to the data supporting the validity around a therapeutic such that it can advance further through other funding mechanisms, such as the small business program (https://urldefense.proofpoint.com/v2/url?u=https-3A__sbir.nih.gov_niddk_index&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=WdhVA7LVBxxZFMapOhBO8mYE8EtpCVPBO5Ub4a5K7a0&s=o2BfY54vzWWMEj_lzVM3h5cEkE8OM0os95c6h69QJ0M&e= ). Due November 12, 2019; July 14, 2020; November 12, 2020; July 14, 2021; and November 12, 2021. Med-RA deadline to receive draft documents for November 2019 deadline: October 29. Research to Understand and Inform Interventions that Promote the Research Careers of Individuals in the Biomedical Sciences (R01 ? Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) encourages applications that propose research designed to test training, mentoring, and networking interventions intended to enhance research-oriented individuals? interest, motivation, persistence and preparedness for careers in the biomedical research workforce. Funded projects are expected to produce research findings that will guide the design and implementation of interventions in a variety of academic settings and career levels to enhance the diversity of the biomedical research workforce. Standard dates apply. Expires January 8, 2022. Med-RA deadline to receive draft documents for October 2019 deadline: September 23. Non-Invasive Neurostimulation in AD/ADRD (R01 Clinical Trial Optional) The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies using non-invasive neurostimulation/neuromodulation in the treatment of Alzheimer?s disease (AD) or Alzheimer?s disease-related dementias (ADRD). The goal of this FOA is to establish initial efficacy of neurostimulation/neuromodulation in the treatment of AD/ADRD or to refine these interventions for AD/ADRD patients. Multimodal or combination interventions are allowed, provided the focus and innovative component is neurostimulation. Applications that seek to develop devices, tools, or invasive techniques are outside the scope of this FOA. Standard dates apply. Expires September 8, 2022. Med-RA deadline to receive draft documents for October 2019 deadline: September 23. Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) also when associated with HIV/AIDS. Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. In studies with a large number of sites, it is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting. Standard dates apply. Expires January 8, 2022. Med-RA deadline to receive draft documents for October 2019 deadline: September 23. For postdocs: NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed) The NIAID New Innovator Awards supports post-doctoral investigators of exceptional creativity who propose highly innovative bold new research with the potential to produce a major impact on broad, important problems in biomedical research of priority to NIAID. Applications from individuals with diverse backgrounds and in any topic relevant to the mission of NIAID are welcome. Due October 10, 2019; October 14, 2020; and October 13, 2021. Med-RA deadline to receive draft documents for October 2019 deadline: September 26. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Wed Jul 3 13:55:32 2019 From: Research at med.fsu.edu (Med Research) Date: Wed, 3 Jul 2019 17:55:32 +0000 Subject: FDOH FY 2019-2020 Bankhead-Coley, James and Esther King and Live Like Bella grant programs In-Reply-To: <678887EBDC79FB438BFD062B064C59A40136DEF94E@FSUCOM128.med.ad.fsu.edu> References: <678887EBDC79FB438BFD062B064C59A40136DEF94E@FSUCOM128.med.ad.fsu.edu> Message-ID: <60E19361B71BE04F835C1FB3C18361BE019043FEC3@FSUCOM128.med.ad.fsu.edu> The Florida Department of Health recently released funding announcements for the Bankhead-Coley, James and Esther King, and Live Like Bella grant programs. Each program requires a Letter of Intent (LOI) to be submitted through the FDOH intake sites listed below. LOIs are due by July 26 at 5:00 PM. Please notify COM Med-RA (research at med.fsu.edu) if you intend to apply for these programs ? letters of intent include institutional information that should be verified by our office prior to submittal. View this email in your browser [https://urldefense.proofpoint.com/v2/url?u=https-3A__gallery.mailchimp.com_4dbaa4a3333ef33c6e55dfbc3_images_f3f8ab1e-2Da4c8-2D4b81-2D9cca-2Decefd1f56476.jpg&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=QSEBrDXdHrWphQ1AoBhjdDegZvtPc-F1p9Qysaoi9a8&s=llj6FB66VqOGZdGMwDOuq2dyibnXV7uiPCxti61bg38&e= ] The intake sites for the FY 2019-2020 Bankhead-Coley Cancer Research Program, James and Esther King Biomedical Research Program, and Live Like Bella Pediatric Cancer Research are now accepting Letters of Intent. You may access these sites by following the links below. Bankhead-Coley Cancer Research Program intake site: https://urldefense.proofpoint.com/v2/url?u=https-3A__peernet.orau.org_Account_Login-3FintakeId-3Dd81fcb1c-2Db866-2De911-2D813f-2D86dac357523e-26isIntakeSubmission-3DTrue&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=QSEBrDXdHrWphQ1AoBhjdDegZvtPc-F1p9Qysaoi9a8&s=3zV1pODZZHbMR26lwgVd8Y3ebSOY8kvTf6X_PJNhq9Y&e= James and Esther King Biomedical Research Program intake site: https://urldefense.proofpoint.com/v2/url?u=https-3A__peernet.orau.org_Account_Login-3FintakeId-3Db828074a-2Dad96-2De911-2D8142-2D0050568131c9-26isIntakeSubmission-3DTrue&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=QSEBrDXdHrWphQ1AoBhjdDegZvtPc-F1p9Qysaoi9a8&s=_diVn7jLIKzV1iwCJjuNs_nN0Zfx251TfAne3auHUkM&e= Live Like Bella Pediatric Cancer Research Initiative intake site: https://urldefense.proofpoint.com/v2/url?u=https-3A__peernet.orau.org_Account_Login-3FintakeId-3Dc17d1250-2Dad96-2De911-2D8142-2D0050568131c9-26isIntakeSubmission-3DTrue&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=QSEBrDXdHrWphQ1AoBhjdDegZvtPc-F1p9Qysaoi9a8&s=Fv2K6Gr9yaUbVfMYHcOcmBfay9SjuWyCP305GktWGVs&e= For further information about these funding opportunities, please visit our program website at https://urldefense.proofpoint.com/v2/url?u=http-3A__www.floridahealth.gov_provider-2Dand-2Dpartner-2Dresources_research_funding-2Dopportunity-2Dannouncements_index.html&d=DwIGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=QSEBrDXdHrWphQ1AoBhjdDegZvtPc-F1p9Qysaoi9a8&s=ifPUFpyfY2940Xf18q51Sd7qA_aCvt48YqoJ4mgcz-k&e= . If you have any questions about these programs, please email us at Research at flhealth.gov. [Twitter] [Facebook] [Website] Want to change how you receive these emails? You can update your preferences or unsubscribe from this list. Send questions to Research at flhealth.gov. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Wed Jul 24 09:20:54 2019 From: Research at med.fsu.edu (Med Research) Date: Wed, 24 Jul 2019 13:20:54 +0000 Subject: Weekly Funding Opportunities Message-ID: Robert Wood Johnson Foundation: Health Care's Role in Meeting Patients' Needs The purpose of this call for proposals is to identify grantees who can lead an effort to provide: Part I: Clear Principles that set a high standard for the health care sector to provide equitable care that fully addresses people's physical, emotional, and social needs; and Part II: Guidance for implementing care delivery that is fully responsive to patients' goals, needs, and life circumstances, using maternal morbidity and mortality as a case example. We expect that these component parts may be led by separate organizations and we invite applicants to apply to lead either one or both component parts. The goals of the program are to: * Use evidence and engagement to articulate a set of principles describing bold aspirations for the health care sector to be responsive to patients' goals, needs, and life circumstances, along the full spectrum of population health improvement activities. These principles should be supported by a set of clear, tested messages that resonate with audiences we aim to reach and influence (Part I, Clear Principles); * Demonstrate-with concrete examples, and using the principles identified in Part I-how health care can and should help the people they serve live their healthiest lives, with a focus on making change within health care delivery systems (Part II, Guidance); * Identify and execute communications strategies targeted to health care leaders and stakeholders (Parts I and II, Clear Principles and Guidance). $2-3M (depending on Part applied for) for two-year projects. Brief proposals due August 15, 2019. Med-RA deadline to receive draft documents: August 1, 2019. American Hearing Health Foundation: Meniere's Disease Research Through this program, grants of up to $25,000 will be awarded in support of research on the causes, diagnosis, and/or treatment of Meniere's disease, with a focus on the hearing or balance functions of the ear. Basic and clinical studies that investigate aspects of the auditory and vestibular systems, including but not limited to genetics, neurotology, anatomy, auditory processing, molecular and cellular biology, therapeutic studies, and investigations of current or experimental devices (i.e., cochlear implants), may be proposed. Due August 15, 2019. Med-RA deadline to receive draft documents: August 1, 2019. American Hearing Research Foundation Grants: Hearing and Balance Disorders of the Inner Ear and Related Topics Through this program, six to ten grants of up to $50,000 each will be awarded in support of research on various aspects of hearing and balance disorders related to the inner ear. Both basic and clinical research that investigates aspects of the auditory and vestibular systems, including but not limited to genetics, neurotology, anatomy, auditory processing, molecular and cellular biology, therapeutic studies, and investigations of current or experimental devices (i.e., cochlear implants), may be proposed. Priority will be given to investigators early in their careers who need seed funding to generate results and data that can be used to support applications for larger grants (i.e., NIH) in the future. Due August 15, 2019. Med-RA deadline to receive draft documents: August 1, 2019. Steven & Alexandra Cohen Foundation: Lyme and Tickborne Disease Initiative The foundation is requesting new proposals in the following areas: diagnostics for Lyme and other tickborne diseases; pathogenesis of post-treatment Lyme disease syndrome (PTLDS) and/or persistent symptoms after confirmed or suspected Lyme disease; pathogenesis of co-infection /co-morbidity; pathogenesis of other tickborne disease; therapeutic development for tickborne disease; economic analysis of Lyme and tickborne disease diagnosis and treatment; and support for new/emerging researchers or clinicians. Grants will support discrete, time-bound projects over a period of one to four years. After a scientific review, the foundation will announce its funding decisions between September 15 and October 15. Projects requesting more than $300,000 in any year will receive additional financial review. Due August 15, 2019. Med-RA deadline to receive draft documents: August 1, 2019. Russell Sage Foundation: Decision Making and Human Behavior in Context This initiative will support innovative research on decision making across the social sciences that examines causes, consequences, processes, or context from a behavioral or alternative perspective. We seek to support a wide range of research on decision-making in context by scholars in psychology, political science, sociology, and other social science fields who are pursuing questions consistent with the aims of the Foundation. This initiative will support research proposals from multiple methodological perspectives that will further our understanding of decision making processes and human behavior in the contexts of work, race, ethnicity, immigration, and social inequality, broadly conceived, in the U.S. Priority will be given to research related to our core programs and other special initiatives. Limited consideration will be given to projects that test well-established behavioral effects without examining the overarching context or the underlying mechanisms. RSF is open to a range of questions consistent with its mission, and has a particular interest in the following research areas: * Biases and Misperceptions * Motivations and Incentives * Habits and Behavior Change * Affect and Emotions * Networks and Contexts Letter of inquiry due August 19, 2019. Med-RA deadline to receive draft documents: August 5, 2019. Elsa U. Pardee Foundation: Cancer Research Grants The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. The Foundation particularly encourages grant applications for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified. By design, there are no limits set on the grant amount that can be requested. It must be reasonably and clearly supported by the scope of the project outlined in the application. Due August 31 and December 31, 2019. Med-RA deadline to receive draft documents for August deadline: August 16, 2019. Amyloidosis Foundation Research Grants The Amyloidosis Foundation focuses on raising awareness in the medical field of amyloidosis, a group of diseases in which abnormal protein, known as amyloid fibrils, builds up in tissue; educating medical professionals through its Grand Rounds program and attendance at medical conferences; prioritizing a research agenda through grants and partnership with the Amyloidosis Research Consortium; and empowering patients through its comprehensive range of services, including accurate, up-to-date information. To that end, the foundation will award grants of up to $50,000 in support of basic biomedical and clinical research related to systemic amyloidosis. To be eligible, applicants must be within ten years of completion of their postdoctoral studies or clinical fellowship and have a mentor. Due September 13, 2019. Med-RA deadline to receive draft documents: August 30, 2019. Regulation of Brain Regional and Cell Type Specific Proteome Dynamics in Alzheimer's Disease (R21 / R01 Clinical Trial Not Allowed) R21 This Funding Opportunity Announcement (FOA) invites early stage innovative and exploratory research focusing on understanding the regulation of brain regional and cell type-specific protein dynamics in Alzheimer's disease (AD). In particular, this FOA seeks applications proposing to develop novel proteomic platforms and animal models to further understanding of the alteration of a single-cell neuronal cell proteome in the central nervous system (CNS) during the course of aging and AD. R01 This FOA invites innovative research focused on understanding the regulation of brain regional and cell-type-specific proteome dynamics in AD. Specifically, this FOA encourages collaborative approaches to design and implement novel, single-cell-based proteomic platforms to comprehensively characterize the dynamics of neuronal proteomes during the course of aging and AD. Due October 23, 2019. Med-RA deadline to receive draft documents: October 9, 2019. Infectious Diseases Society of America Foundation: Alzheimer's Research Grant Alzheimer's disease is devastating for the 47 million people worldwide living with the disease, robbing them of memories and the ability to function independently. Researchers have long sought the cause and worked to develop a cure, without significant success. Some evidence suggests that Alzheimer's may be triggered or driven by an infectious agent or microbial mechanism. Could this be the missing link to lead to a cure for Alzheimer's disease? Determined to advance science regarding this possible connection, the IDSA Foundation is offering up to five one-time, $100,000 grants to researchers working to identify a microbial link to Alzheimer's disease. The IDSA Foundation research grants are designed to: * Obtain evidence that an infectious agent or microbial community is correlated to Alzheimer's disease * Promote novel research in the field of microbial triggers for Alzheimer's disease To be eligible for a grant, research must be narrowly focused on identifying the possible role of an infectious agent or agents in causing Alzheimer's disease. Awards will support innovative research, including basic, clinical and/or non-traditional approaches. Due November 30, 2019. Med-RA deadline to receive draft documents: November 13, 2019. American Congress of Obstetricians and Gynecologists Warren H. Pearse Women's Health Policy Research Award This research award will provide $10,000 to support research that explores an aspect of health care policy that assists, defines, or restricts the ability of a physician to deliver health care to women in the general population, or in a specific area. Due December 11, 2019. Med-RA deadline to receive draft documents: November 22, 2019. To search for additional funding opportunities, please visit CoM's unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Mon Jul 29 17:08:31 2019 From: Research at med.fsu.edu (Med Research) Date: Mon, 29 Jul 2019 21:08:31 +0000 Subject: Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE0190446DD8@FSUCOM128.med.ad.fsu.edu> Novel Technology Tools to Facilitate Research Using Next Generation Patient-derived Cancer Models (U01 Clinical Trial Not Allowed) Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support the development of technology tools that will facilitate, accelerate, and/or enhance research using advanced human-derived next generation cancer models (NGCMs), such as organoids, conditionally reprogrammed cells, and others. The studies proposed under this FOA must focus entirely on the next generation cancer models developed under the auspices of an international consortium with NCI participation, Human Cancer Models Initiative. "Technology tools" to be developed under this FOA may include new and/or optimized laboratory methods, reagents/reference materials, agents for NGCMs perturbation or screening read-outs, and/or software/bioinformatics tools for data processing and/or facilitated/enhanced interpretations. (The development of new hardware/equipment will not be supported). The proposed technology tools are expected to a) facilitate the utilization of the cancer models, e.g., in terms of increasing robustness, rigor, and/or reproducibility of results, b) enable advanced interpretations of experiments in which these model are used, c) design and test genomic editing/manipulating reagents for all cancer and NGCM types, and d) develop robust approaches to method standardization, quality assurance/control, etc., that could serve as routine workflows/best practices for use in a wide range of laboratories. The collective outcomes of projects under this FOA should facilitate the adoption of NGCMs by the research community and expedite sharing and validating of NGCMs-derived results. The new tools and broader use of NCGMs are expected to contribute to the progress in such areas as the identification of novel therapeutic targets, mechanisms of resistance, development of diagnostic and/or predictive biomarkers, and other aspects relevant to precision oncology. Due August 30, 2019. Med-RA deadline to receive draft documents: August 19, 2019. BRAIN Initiative: Proof of Concept Development of Early Stage Next Generation Human Brain Imaging (R01 Clinical Trial Not Allowed) This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support early stage development of entirely new and novel noninvasive human brain imaging technologies and methods that will lead to transformative advances in our understanding of the human brain. The FOA solicits unusually bold and potentially transformative approaches and supports small-scale, proof-of-concept development based on exceptionally innovative, original and/or unconventional concepts. Due September 3, 2019. Med-RA deadline to receive draft documents: August 19, 2019. Computational Methods for Integrating Tissue and Single Cell Genomic Data from the Brain (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement is to support the development or application of advanced computational and statistical tools to integrate brain tissue and single-cell genomic data in order to advance our understanding of the cell type-specific gene regulatory networks and biological pathways involved in the pathogenesis and pathophysiology of major mental disorders. Due September 3, 2019. Med-RA deadline to receive draft documents: August 19, 2019. BRAIN Initiative: Development of Next Generation Human Brain Imaging Tools and Technologies (U01 Clinical Trial Not Allowed) This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support full development of entirely new or next generation noninvasive human brain imaging tools and methods that will lead to transformative advances in our understanding of the human brain. The FOA seeks innovative applications that are ready for full-scale development of breakthrough technologies with the intention of delivering working tools. Due September 3, 2019; September 3, 2020; and September 3, 2021. Med-RA deadline to receive draft documents for 2019 deadline: August 19, 2019. BRAIN Initiative: Non-Invasive Neuromodulation - New Tools and Techniques for Spatiotemporal Precision (R01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) solicits grant applications in two related but distinct areas. The first area is in the development and testing of novel tools and methods of neuromodulation that go beyond the existing forms of neural stimulation. The second distinct area that this FOA seeks to encourage is the optimization of existing stimulation methods. Due September 3, 2019 and February 14, 2020. Med-RA deadline to receive draft documents for September deadline: August 19, 2019. Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP). Other publicly available data sets would be considered depending on the analyses to be conducted; however, nationally representative analyses will receive priority. Applications not using nationally representative data sets will need to provide justification why the data set is unique, and why the research questions cannot be answered from a (publicly available) nationally representative data set. This FOA encourages the analyses of public use datasets that may inform tobacco regulatory actions in the United States (U.S.). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). Due October 8, 2019; July 20, 2020; and March 8, 2021. Med-RA deadline to receive draft documents for October deadline: September 24, 2019. Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed); Center for Tobacco Products The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey (NHANES), the National Heart, Lung and Blood Institute's (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. While other publicly available repositories would be considered, depending on analyses to be conducted, nationally representative analyses will receive priority. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set. Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP). Due October 8, 2019; August 7, 2020; and March 8, 2021. Med-RA deadline to receive draft documents for October deadline: September 24, 2019. Molecular Mechanisms of Blood-Brain Barrier Function and Dysfunction in Alzheimer's disease and Alzheimer's related dementias (AD/ADRD) (R01 Clinical Trial Not Allowed) The goal of this initiative is to elucidate the mechanistic links between blood brain barrier (BBB) dysfunction, Alzheimer's Disease (AD) and AD-Related Dementias, and how related comorbidities impact the basic molecular mechanisms of BBB health and function. Due October 9, 2019. Med-RA deadline to receive draft documents: September 25, 2019. FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed) The purpose of the FDA (R13) Scientific Conference Grant Program is to facilitate the provision of federal financial assistance in support of high-quality conferences and scientific meetings designed to research and investigate a topic clearly aligned with the FDA mission. The FDA recognizes the value of supporting high quality conferences and scientific meetings relevant to its mission and to the public health. A conference or scientific meeting is defined as a symposium, seminar, workshop, or any formal meeting, whether conducted face-to-face or virtually to exchange information and explore a defined subject, issue, or area of concern impacting the public's health within the scope of the FDA's mission. Permission to submit a conference grant application does not assure funding or funding at the level requested. FDA will not issue a conference grant award unless it can be issued before the conference start date. Due October 11, 2019; April 13, 2020; October 13, 2020; April 12, 2021; October 12, 2021; April 12, 2022; and October 11, 2022. Note: Prior approval (advance permission to apply) in the form of a Letter of Intent is required before submission of an application for conference support. Advance permission to submit an application must be requested early in the process and must be submitted no later than 8 weeks before the selected application due date. Letter(s) of Intent received after 8 weeks prior to the application submission date will not be accepted. Med-RA deadline to receive draft documents for 2019 Letter of Intent deadline: August 5, 2019. To search for additional funding opportunities, please visit CoM's unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: